Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors
July 10, 2023 08:00 ET
|
Longeveron
MIAMI, July 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
Longeveron Files Registration Statement for Rights Offering
June 27, 2023 18:07 ET
|
Longeveron
MIAMI, June 27, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
Longeveron Welcomes Three New Prominent Board Members
June 13, 2023 08:30 ET
|
Longeveron
Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of Stockholders MIAMI, June 13, 2023 (GLOBE NEWSWIRE) --...
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 12, 2023 08:00 ET
|
Longeveron
-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit -- -- First patient dosed in Phase 2...
Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome
May 09, 2023 08:30 ET
|
Longeveron
- Children in the ELPIS I trial had 100% survival up to 5 years of age after receiving Lomecel-BTM compared to 20% mortality rate observed from historical control data - - Data reinforce potential...
Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023
May 08, 2023 08:30 ET
|
Longeveron
MIAMI, May 08, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan
April 19, 2023 08:59 ET
|
Longeveron
-- The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population -- -- First-in-human clinical trial of Lomecel-B™ in Japan -- -- Study will also assess...
Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 10, 2023 08:00 ET
|
Longeveron
-- Full results from ELPIS I trial published in European Heart Journal Open – -- First patient to be randomized in Japan Aging-Related Phase 2 study in Q1 – ...
Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
March 06, 2023 08:30 ET
|
Longeveron
MIAMI, March 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical...
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
February 28, 2023 08:30 ET
|
Longeveron
Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over 35 years of experience with focus on drug approval...